Nanjing Vishee Medical Technology Co., Ltd. Class A

As of June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A carries a market capitalization of 5.10B, placing it among publicly traded companies globally. Its enterprise value stands at 4.24B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Nanjing Vishee Medical Technology Co., Ltd. Class A's next confirmed earnings release is scheduled for October 27, 2026.

As of June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A has 95.77M shares outstanding.

As of June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 29.61. The price-to-sales ratio is 10.66, and the price-to-book ratio stands at 3.02.

As of June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A trades at an EV/EBITDA multiple of 21.90 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.87 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 21.90 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.24B versus a market cap of 5.10B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A maintains a current ratio of 9.38, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.02, indicating conservative leverage, while an interest coverage ratio of 314.55 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A posted a return on equity (ROE) of 10.27, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 10.02 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.54, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.21, useful for judging operating efficiency across full business cycles. The company generates approximately 751,844.78 in revenue per employee across its workforce of 636.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.23 indicates how many times Nanjing Vishee Medical Technology Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A recorded 23.21M in income tax expense. That works out to an effective tax rate of 11.88, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 195.36M, leaving 172.15M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A's stock has declined approximately 15.69% over the past 52 weeks. The 50-day moving average sits at 44.38, while the 200-day moving average is 53.13.

Over the twelve months ended June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A generated 478.17M in revenue and converted that into 172.15M in net income, yielding earnings per share of 1.80. EBITDA reached 193.73M, while operating income came in at 141.62M.

As of June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A holds 859.61M in cash and equivalents against 365,305.04 in total debt, resulting in a net debt position of -859.61M. Total book value stands at 1.69B, with working capital of 859.67M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A posted a gross margin of 65.65, reflecting its pricing power and cost economics. The operating margin of 29.62 and net profit margin of 36.00 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A paid dividends of -0.01 per share. The dividend payout ratio of -0.58 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Nanjing Vishee Medical Technology Co., Ltd. Class A's most recent stock split took place on June 5, 2024 with a 5:7 split ratio.

As of June 30, 2026, Nanjing Vishee Medical Technology Co., Ltd. Class A has an Altman Z-Score of 31.36, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.